Tips from Other Journals

Interferon-alfa in Children with Chronic Hepatitis C



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 1998 Aug 1;58(2):505.

Interferon-alfa is an accepted treatment for chronic hepatitis C in adults, with a response rate (defined as normalization of alanine aminotransferase [ALT] values) of about 50 percent and a relapse rate in the first year of 50 percent. Jonas and colleagues conducted an open-labeled prospective trial to determine the safety and efficacy of interferon-alfa-2a therapy in children with chronic hepatitis C virus.

A total of 21 children with at least two ALT determinations more than 1.5 times the upper limit for at least six months completed the study. Treatment consisted of 3 million U of interferon-alfa-2a administered subcutaneously three times weekly for six months. Treatment was extended to one year in patients found to be responding at six months.

Four children (19 percent) had complete response to treatment at the end of six months, with normal ALT values and no detectable RNA for hepatitis C virus. An additional eight children (38 percent) were partial responders, with at least a 50 percent improvement in ALT values. Two of the responders who received prolonged therapy remained RNA–negative for hepatitis C virus, with normal ALT values. Three of the partial responders who received 12 months of treatment became complete responders, and this response was sustained. There were no statistically significant factors associated with response; however, the small sample size limited the ability to detect differences in variables. Side effects of treatment included fever and malaise in virtually every child early in the treatment. Seven of the children participating in the study (33 percent) lost HCV RNA and had normalization of ALT; all of these children had sustained response for at least six months, and five had sustained response for 12 months.

The authors conclude that although the response rate of 33 percent for children is less than the 50 percent rate typically reported for adults at one year, treatment with interferon-alfa has some efficacy in children with chronic hepatitis C infection. Children who have complete or partial response at six months should undergo prolonged treatment. Side effects were minimal. The most worrisome side effect was weight loss, which occurred in one half of the children treated. All of these children regained the lost weight after the conclusion of therapy. No long-term effects of interferon-alfa therapy were noted in follow-up of up to 36 months' duration.

Jonas MM, et al. Interferon-alpha treatment of chronic hepatitis C virus infection in children. Pediatr Infect Dis J. March 1998;17:241–6.


Copyright © 1998 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article